Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2425 SEK | -3.00% | +20.05% | -97.58% |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 | |
May. 16 | Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.58% | 35.61M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.43% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar